Joachim Listing

27.1k total citations · 5 hit papers
179 papers, 14.8k citations indexed

About

Joachim Listing is a scholar working on Rheumatology, Hematology and Immunology. According to data from OpenAlex, Joachim Listing has authored 179 papers receiving a total of 14.8k indexed citations (citations by other indexed papers that have themselves been cited), including 163 papers in Rheumatology, 66 papers in Hematology and 61 papers in Immunology. Recurrent topics in Joachim Listing's work include Rheumatoid Arthritis Research and Therapies (127 papers), Spondyloarthritis Studies and Treatments (107 papers) and Autoimmune and Inflammatory Disorders Research (65 papers). Joachim Listing is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (127 papers), Spondyloarthritis Studies and Treatments (107 papers) and Autoimmune and Inflammatory Disorders Research (65 papers). Joachim Listing collaborates with scholars based in Germany, United States and United Kingdom. Joachim Listing's co-authors include Joachim Sieper, Jürgen Braun, Martín Rudwaleit, A. Zink, Hildrun Haibel, Xenofon Baraliakos, J. Brandt, Anja Strangfeld, H. Zeidler and Denis Poddubnyy and has published in prestigious journals such as The Lancet, Annals of the Rheumatic Diseases and Atherosclerosis.

In The Last Decade

Joachim Listing

175 papers receiving 14.1k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial

2002 953 citations Jürgen Braun, J. Brandt et al. profile →
The early disease stage in axial spondylarthritis: Results from the german spondyloarthritis inception cohort

2009 512 citations Martín Rudwaleit, Hildrun Haibel et al. profile →
Infections in patients with rheumatoid arthritis treated with biologic agents

2005 512 citations Joachim Listing, Anja Strangfeld et al. profile →
ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis

2008 455 citations Désirée van der Heijde, E. Lie et al. Annals of the Rheumatic Diseases profile →
The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment

2012 368 citations Joachim Listing, A. Zink et al. Lara D. Veeken profile →

Peers

Countries citing papers authored by Joachim Listing

Since Specialization

Citations

This map shows the geographic impact of Joachim Listing's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joachim Listing with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joachim Listing more than expected).

Fields of papers citing papers by Joachim Listing

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joachim Listing. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joachim Listing. The network helps show where Joachim Listing may publish in the future.

Co-authorship network of co-authors of Joachim Listing

This figure shows the co-authorship network connecting the top 25 collaborators of Joachim Listing. A scholar is included among the top collaborators of Joachim Listing based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joachim Listing. Joachim Listing is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Comparison of the effect of treatment with NSAIDs added to anti-TNF therapy versus anti-TNF therapy alone on the progression of structural damage in the spine over 2 years in patients with radiographic axial spondyloarthritis from the randomised-controlled CONSUL trial 2024 ·Annals of the Rheumatic Diseases ·Fabian Proft, Murat Torğutalp, Burkhard Muche, Valeria Ríos Rodríguez, Joachim Listing, Mikhail Protopopov, Judith Rademacher, Hildrun Haibel, Laura Spiller, (unknown), (unknown), (unknown), Uta Kiltz, (unknown), (unknown), Joachim Sieper, Denis Poddubnyy	9
2	Complement proteins in axial spondyloarthritis: associations with disease activity and TNFi treatment response in a multicentre RCT 2024 ·Rheumatology Advances in Practice ·(unknown), Anne Troldborg, Murat Torğutalp, Anne Gitte Loft, Steffen Thiel, Burkhard Muche, Valeria Ríos Rodríguez, Mikhail Protopopov, Joachim Listing, Joachim Sieper, Denis Poddubnyy, Fabian Proft	0
3	The Sensitivity to Change of the ASAS Health Index in an Observational Real-Life Cohort Study 2022 ·The Journal of Rheumatology ·Anne C. Regierer, Anja Weiß, Uta Kiltz, Joachim Sieper, (unknown), M. Bohl-Bühler, Herbert Kellner, Denis Poddubnyy, A. Zink, Jürgen Braun, Joachim Listing, Anja Strangfeld	3
4	Hydroxychloroquine in patients with inflammatory and erosive osteoarthritis of the hands: results of the OA-TREAT study—a randomised, double-blind, placebo-controlled, multicentre, investigator-initiated trial 2021 ·RMD Open ·Claudia Kedor, J. Detert, Rolf Rau, Siegfried Wassenberg, Joachim Listing, Klaus Pietzner, T. Braun, W. Hermann, Stefan M. Weiner, Frank Buttgereit, Gerd R Burmester	24
5	Canakinumab for Treatment of Adult-Onset Still's Disease to Achieve Reduction of Arthritic Manifestation (CONSIDER): phase II, randomised, double-blind, placebo-controlled, multicentre, investigator-initiated trial 2020 ·Annals of the Rheumatic Diseases ·Claudia Kedor, Joachim Listing, Jan Zernicke, Anja Weiß, Frank Behrens, Norbert Blank, Jörg Henes, Joern Kekow, Andrea Rubbert‐Roth, Hendrik Schulze‐Koops, Eva Seipelt, Christof Specker, Eugen Feist	64
6	Diagnostic accuracy of inflammatory back pain for axial spondyloarthritis in rheumatological care 2018 ·RMD Open ·Denis Poddubnyy, Johanna Callhoff, I. Spiller, Joachim Listing, Jürgen Braun, Joachim Sieper, Martín Rudwaleit	47
7	FRI0130 Rates and risk factors of new-onset psoriasis under different biologic agents and conventional synthetic dmard treatment 2017 ·Annals of the Rheumatic Diseases ·Anja Strangfeld, (unknown), Adrian Richter, B. Manger, GR Burmester, (unknown), Siegfried Wassenberg, Anna Zink, Joachim Listing	2
8	Hydroxychloroquine in patients with inflammatory and erosive osteoarthritis of the hands (OA TREAT): study protocol for a randomized controlled trial 2014 ·Trials ·J. Detert, Klaus Pietzner, Joachim Listing, (unknown), T. Braun, Siegfried Wassenberg, Rolf Rau, Frank Buttgereit, Gerd R Burmester	18
9	Frequency and duration of drug-free remission after 1 year of treatment with etanercept versus sulfasalazine in early axial spondyloarthritis: 2 year data of the ESTHER trial 2012 ·Annals of the Rheumatic Diseases ·In‐Ho Song, Christian E. Althoff, Hildrun Haibel, Kay‐Geert Hermann, Denis Poddubnyy, Joachim Listing, Anja Weiß, (unknown), Gerd R Burmester, M. Bohl-Bühler, Bruce Freundlich, Martín Rudwaleit, Joachim Sieper	68
10	Effects of etanercept versus sulfasalazine in early axial spondyloarthritis on active inflammatory lesions as detected by whole-body MRI (ESTHER): a 48-week randomised controlled trial 2011 ·Annals of the Rheumatic Diseases ·(unknown), Kay‐Geert Hermann, Hildrun Haibel, C Althoff, Joachim Listing, (unknown), Andreas Krause, M. Bohl-Bühler, B Freundlich, Martín Rudwaleit, J. Sieper	197
11	Persistent clinical efficacy and safety of infliximab in ankylosing spondylitis after 8 years--early clinical response predicts long-term outcome 2011 ·Lara D. Veeken ·Xenofon Baraliakos, Joachim Listing, (unknown), Hildrun Haibel, Rieke Alten, Gerd R Burmester, Andreas Krause, Stefan Schewe, Matthias Schneider, Helge B. D. Sørensen, René Schmidt, Joachim Sieper, (unknown)	88
12	RADIOGRAPHIC FINDINGS AFTER 5 YEARS OF INFLIXIMAB TREATMENT IN PATIENTS WITH ANKYLOSING SPONDYLITIS 2010 ·Clinical and Experimental Rheumatology ·Xenofon Baraliakos, F. Heldmann, D. van der Heijde, Joachim Listing, Joachim Sieper, Alessandra Oortwijn, Rebecca Bolce, Jürgen Braun	1
13	Development of a radiographic scoring tool for ankylosing spondylitis only based on bone formation: Addition of the thoracic spine improves sensitivity to change 2009 ·Arthritis Care & Research ·Xenofon Baraliakos, Joachim Listing, Martín Rudwaleit, Joachim Sieper, Jürgen Braun	62
14	Serum levels of biomarkers of bone and cartilage destruction and new bone formation in different cohorts of patients with axial spondyloarthritis with and without tumor necrosis factor-alpha blocker treatment 2008 ·Arthritis Research & Therapy ·Heiner Appel, Louise M.E. Janssen, Joachim Listing, (unknown), Martín Rudwaleit, Joachim Sieper	46
15	ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis breakdown → 2008 ·Annals of the Rheumatic Diseases ·Désirée van der Heijde, E. Lie, Tore K Kvien, Joachim Sieper, Filip Van den Bosch, Joachim Listing, Joseph M. Braun, R. Landewé	455
16	Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti–tumor necrosis factor α agents 2007 ·Arthritis Care & Research ·Jürgen Braun, Xenofon Baraliakos, Joachim Listing, John C. Davis, D. van der Heijde, Hildrun Haibel, Martín Rudwaleit, Joachim Sieper	145
17	MRI in predicting a major clinical response to anti-tumour necrosis factor treatment in ankylosing spondylitis 2007 ·Annals of the Rheumatic Diseases ·Martín Rudwaleit, (unknown), (unknown), Joachim Listing, Jürgen Braun, Joachim Sieper	217
18	Radiographic progression in patients with ankylosing spondylitis after 4 yrs of treatment with the anti-TNF- antibody infliximab 2007 ·Lara D. Veeken ·Xenofon Baraliakos, Joachim Listing, J. Brandt, Hildrun Haibel, Martín Rudwaleit, Joachim Sieper, Jürgen Braun	138
19	Dosisanpassung bei Patienten mit rheumatoider Arthritis unter Therapie mit Infliximab in der rheumatologischen Versorgung in Deutschland 2006 ·Zeitschrift für Rheumatologie ·A. Zink, Joachim Listing, Anja Strangfeld, Erika Gromnica‐Ihle, W. Demary, Matthias Schneider	6
20	Disability and handicap in rheumatoid arthritis and ankylosing spondylitis--results from the German rheumatological database. German Collaborative Arthritis Centers. 2000 ·PubMed ·A. Zink, Jürgen Braun, Joachim Listing, J. Wollenhaupt	262

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact